+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Dental Pain Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • ID: 4830050
  • Drug Pipelines
  • August 2019
  • Region: Global
  • 35 pages
  • VPA Research

FEATURED COMPANIES

  • AfaSci Inc
  • Nevakar LLC
High levels of pipeline activity are being observed in Dental Pain treatment during 2019. Clinical development activities are being undertaken by more than 5 companies including AfaSci Inc, Nevakar LLC, Pacira Pharmaceuticals Inc, Laboratorios Del Dr Esteve SA and others.

A Significant contribution to the Dental Pain pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Dental Pain pipeline included 4 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Dental Pain condition and increased access to investments is encouraging growth of Dental Pain drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Dental Pain drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Dental Pain therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Dental Pain pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Dental Pain. Further, orphan drug status, fast track designation, grants awarded and other special status for Dental Pain pipeline compounds are also included.

This study was produced independently by the publisher from their proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Dental Pain pipeline and formulate effective research and development strategies.

Research Methodology

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Dental Pain Pipeline candidates
  • Pre-clinical Phase: Discovery, research, pre-clinical
  • Early Phase: Phase 1 and Phase 2 Dental Pain drugs
  • Late phase: Phase 3 and in-approval Dental Pain drugs
Companies involved in the Pipeline
  • Company overview
  • Snapshot
  • Dental Pain therapeutic treatment activities
Details for each Dental Pain drug candidate
  • Snapshot
  • Drug Name
  • Alternative Names
  • Company
  • Originator
  • Phase
  • Molecule Type
  • Orphan Drug Status
  • Drug Overview
  • Mechanism of Action
  • Current Status
  • Trial Details
Other details
  • Pre-clinical trials for each drug candidate
  • Clinical trials for each drug candidate
Recent Dental Pain therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AfaSci Inc
  • Nevakar LLC
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Dental Pain- Disease Overview
2.2 Dental Pain- Pipeline Snapshot
2.3 Dental Pain- Pipeline Drugs by Phase
2.4 Dental Pain- Pipeline Drugs by Company
2.5 Dental Pain- Pipeline Drugs by Mechanism of Action

3 Company wise Pipeline Analysis
3.1 AfaSci Inc Dental Pain Drug Pipeline, H2- 2019
3.2 Laboratorios Del Dr Esteve SA Dental Pain Drug Pipeline, H2- 2019
3.3 Nevakar LLC Dental Pain Drug Pipeline, H2- 2019
3.4 Pacira Pharmaceuticals Inc Dental Pain Drug Pipeline, H2- 2019

4 Phase 1 Pipeline Drug Details
4.1 Dental Pain- Phase 1 Drug Details
4.2 Dental Pain- Phase 1 Drug Overview
4.3 Dental Pain- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 Phase 2 Pipeline Drug Details
5.1 Dental Pain- Phase 2 Drug Details
5.2 Dental Pain- Phase 2 Drug Overview
5.3 Dental Pain- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 Phase 3 Pipeline Drug Details
6.1 Dental Pain- Phase 3 Drug Details
6.2 Dental Pain- Phase 3 Drug Overview
6.3 Dental Pain- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 Pre-clinical Phase Pipeline Drug Details
7.1 Dental Pain- Pre-clinical Phase Drug Details
7.2 Dental Pain- Pre-clinical Phase Drug Overview
7.3 Dental Pain- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 Recent News and Developments

9 Appendix
9.1 About the Publisher
9.2 Sources and Research Methodology
Note: Product cover images may vary from those shown
  • AfaSci Inc
  • Nevakar LLC
  • Pacira Pharmaceuticals Inc
  • Laboratorios Del Dr Esteve SA
Note: Product cover images may vary from those shown
Adroll
adroll